A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Bristol-Myers Squibb81 enrolled

Overview

Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world

Study Type

OBSERVATIONAL

Enrollment

Conditions

Renal Cell Carcinoma Kidney Cancer

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment for the first time with Yervoy and Opdivo in accordance with the Japanese package insert will be included in this PMS Exclusion Criteria: * Patients receiving combination therapy with Yervoy and Opdivo for non RCC indication will be excluded from this PMS Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Tokyo, Japan